Biocorrx (BICX)
(Delayed Data from OTC)
$0.75 USD
-0.07 (-8.54%)
Updated Apr 26, 2024 11:36 AM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BICX 0.75 -0.07(-8.54%)
Will BICX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BICX based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for BICX
BioCorRx receives new patent for novel compound to treat pain, depression, and schizophrenia
BioCorRx Inc Board Sees Dual Director Resignations
BioCorRx Inc at SRAX Sequire Biotechnology Conference (Virtual) Transcript
BioCorRx Inc at Benzinga All Access Event Transcript
BioCorRx Inc To Present At The Q1 Investor Summit Conference Transcript